|
|
|
|
GMMMG Consultations |
|
|
On this page you will find proposed changes that are currently going through the GMMMG approval process. This will include consultations on proposed RAG status, updated Formulary Chapters, Pathways or other GMMMG Guidance. You will be able to comment on current proposals via the links in the table below. |
|
|
Title |
Information |
Feedback |
End date |
|
|
24 |
The following actions were proposed at the March 2018 FMESG meeting, approved in principle by GMMMG in April, and are now open for GM wide consultation. Comments are invited up until 5pm Tuesday 15th May 2018 and should be submitted here |
5pm Tuesday |
||
|
23 |
GM Model Framework for dermatology services |
Under direction of the GM Directors of Commissioning the GM Dermatology Group are developing the GM Model Framework for dermatology services. The group has produced a series of educational tools which will help to improve confidence of managing skin in primary care and upskill clinicians in primary care at the same time. Included in the educational pack is: |
5pm Wednesday 2nd May 2018 |
|
|
A GM pathway of care from primary care to tertiary care Refreshed skin chapter 2WW pathway Emollient and steroid ladders |
|
|||
|
A number of these are now opened (see links above) for GM wide consultation in line with the GMMMG approval process. Please submit any comments using the appropriate feedback form links above, this consultation will close at 5pm Wednesday 2nd May 2018. Industry are invited to comment on factual inaccuracy only. |
||||
|
22 |
The Greater Manchester DNP and grey lists have been revised to reflect recent NHS England guidance. Please note that the list contains items previously considered by GMMMG and not included in the NHS England list. Changes to these items are purely editorial, in order to harmonise wording throughout. The list also contains three new items to be considered for inclusion. The revised list is now open for GM-wide consultation for 6 weeks. Industry are invited to comment on factual inaccuracies only. Following consultation the list will be taken forward to AGG for policy development. Comments are invited up until 5pm on Tuesday 22nd May 2018 and should be submitted here. |
5pm Tuesday |
||
|
21 |
On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for ciclosporin for childhood nephrotic syndrome is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 18th May 2018. |
5pm Friday |
||
|
20 |
On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for sulfasalazine for inflammatory bowel disease is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 18th May 2018. |
5pm Friday |
||
|
19 |
Domperidone for paediatric gastro-oesophageal reflux disease |
On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for domperidone for paediatric gastro-oesophageal reflux disease is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 18th May 2018. |
5pm Friday |
|
|
18 |
On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for disulfiram for alcohol dependence is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 18th May 2018. |
5pm Friday |
||
<< Back
